Long-term exposure to even low levels of sulfur dioxide (SO2), an air pollutant with a strong odor, may place people…
Articles by Margarida Maia, PhD
Ofev (nintedanib) more than halved the rate of lung function decline in patients who developed interstitial lung disease (ILD)…
A Phase 3 trial of pamrevlumab, an experimental therapy from FibroGen to treat idiopathic pulmonary fibrosis (IPF), failed…
Insilico Medicine made its entry into Phase 2 clinical testing with INS018_055, a small molecule it discovered and designed…
A new, potentially disease-specific imaging agent may one day allow doctors to identify pulmonary fibrosis (PF) in earlier stages,…
Researchers in the U.S. turned a special type of mouse stem cell into green, glowing lung cells in the lab…
Brilaroxazine, Reviva Pharmaceuticals’ experimental therapy for idiopathic pulmonary fibrosis (IPF), was found to reduce lung inflammation and fibrosis,…
An experimental oral medication Bristol Myers Squibb is developing did better than a placebo at slowing lung function decline…
Researchers have discovered a variant of the usual basal stem cells found in the lungs that may contribute to scarring,…
A high dose of bexotegrast, an oral treatment being developed by Pliant Therapeutics, continues to be well-tolerated for up…